Loviride Properties

Description

Loviride was an antiviral drug manufactured by Janssen that is active against HIV. It is an NNRTI that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride, because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to all NNRTI's.